Literature DB >> 19157720

Heterogeneity of angiogenesis and blood vessel maturation in cartilage tumors.

Thomas Kalinski1, Saadettin Sel, Irina Kouznetsova, Martin Röpke, Albert Roessner.   

Abstract

Cartilage tumors have a special angiogenic phenotype, with blood vessels arranged predominantly in pericartilage fibrous septa and relatively low microvessel density (MVD), except in dedifferentiated chondrosarcomas. To further elucidate angiogenesis in cartilage tumors, we used double-labeling immunohistochemistry to determine microvessel pericyte coverage index (MPI) and proliferating capillary index (PCI), referring to blood vessel maturation and angiogenic activity in enchondromas, conventional chondrosarcomas, and dedifferentiated chondrosarcomas. Altogether, we found high MPIs (>70%) especially in dedifferentiated chondrosarcomas but without a correlation to the grade of malignancy. PCI was significantly higher in conventional chondrosarcomas grades II and III than in enchondromas, chondrosarcomas grade I, and dedifferentiated chondrosarcomas. Thus, PCI positively correlated with the previously reported differential expression of vascular endothelial growth factor (VEGF)-A in cartilage tumors. Altogether, cartilage tumors exhibit a heterogeneous but predominantly mature angiogenic phenotype with differential proliferative activity.

Entities:  

Mesh:

Year:  2009        PMID: 19157720     DOI: 10.1016/j.prp.2008.12.008

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  16 in total

Review 1.  [Inflammation as molecular target in chondrosarcoma].

Authors:  T Kalinski
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

2.  Description of the immune microenvironment of chondrosarcoma and contribution to progression.

Authors:  François A Simard; Iseulys Richert; Alexandra Vandermoeten; Anne-Valérie Decouvelaere; Jean-Philippe Michot; Christophe Caux; Jean-Yves Blay; Aurélie Dutour
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

Review 3.  Pericytes in sarcomas of bone.

Authors:  Le Chang; Vi Nguyen; Alan Nguyen; Michelle A Scott; Aaron W James
Journal:  Med Oncol       Date:  2015-06-16       Impact factor: 3.064

4.  Benign mesenchymal stromal cells in human sarcomas.

Authors:  Alexei Morozov; Robert J Downey; John Healey; Andre L Moreira; Emil Lou; Anna Franceschino; Yildirim Dogan; Roland Leung; Mark Edgar; Michael LaQuaglia; Robert G Maki; Malcolm A S Moore
Journal:  Clin Cancer Res       Date:  2010-12-01       Impact factor: 12.531

5.  [Angiogenesis in cartilage tumors].

Authors:  T Kalinski; A Roessner
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

6.  Diversity of angiogenesis among malignant bone tumors.

Authors:  Tadahiko Kubo; Shoji Shimose; Jun Fujimori; Koji Arihiro; Mitsuo Ochi
Journal:  Mol Clin Oncol       Date:  2012-08-10

7.  Analysis of angiogenic factors and cyclooxygenase-2 expression in cartilaginous tumors- clinical and histological correlation.

Authors:  Francisco Fontes Cintra; Mauricio Etchebehere; José Carlos Barbi Gonçalves; Alejandro Enzo Cassone; Eliane Maria Ingrid Amstalden
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

8.  The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets.

Authors:  E David; F Blanchard; M F Heymann; G De Pinieux; F Gouin; F Rédini; D Heymann
Journal:  Sarcoma       Date:  2011-05-22

9.  Inhibition of chondrosarcoma growth by mTOR inhibitor in an in vivo syngeneic rat model.

Authors:  Jennifer Perez; Anne Valérie Decouvelaere; Thomas Pointecouteau; Daniel Pissaloux; Jean Philippe Michot; Anthony Besse; Jean Yves Blay; Aurélie Dutour
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

Review 10.  Pericytes for the treatment of orthopedic conditions.

Authors:  Aaron W James; Paul Hindle; Iain R Murray; Christopher C West; Tulyapruek Tawonsawatruk; Jia Shen; Greg Asatrian; Xinli Zhang; Vi Nguyen; A Hamish Simpson; Kang Ting; Bruno Péault; Chia Soo
Journal:  Pharmacol Ther       Date:  2016-08-07       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.